Lisata Therapeutics vs Vivosim Labs
Lisata Therapeutics is the larger business, with $170,000 of revenue in fiscal 2025 against $131,000 for Vivosim Labs (1.3 times as much). Vivosim Labs grew faster (-9.0% against -83.0%). Lisata Therapeutics kept more of each dollar of sales as profit: a net margin of -9756.5% against -10567.2%.
| Latest fiscal year | Lisata TherapeuticsLSTA, 2025 | Vivosim LabsVIVS, 2026 |
|---|---|---|
| Revenue | $170,000 | $131,000 |
| Revenue growth | -83.0% | -9.0% |
| Net income | −$16.6m | −$13.8m |
| Operating margin | -10711.2% | -8768.7% |
| Net margin | -9756.5% | -10567.2% |
| Return on equity | -74.7% | — |
| Free cash flow | −$16.0m | −$10.8m |
| Cash | $16.0m | $5.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 21 | 15 |
| Market value | $9.8m | $457,742 |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 18 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 1 sales |